AbbVie, Amgen End Patent Fight Over Humira Biosimilar
AbbVie Inc. and Amgen Inc. on Thursday announced a patent litigation settlement that will keep a biosimilar version of Humira, the world's best-selling drug, out of European pharmacies until 2018 and...To view the full article, register now.
Already a subscriber? Click here to view full article